ACL Share Price

Open 0.01 Change Price %
High 0.01 1 Day 0.00 0.00
Low 0.01 1 Week 0.00 0.00
Close 0.01 1 Month 0.00 0.00
Volume 15000 1 Year 0.00 0.00
52 Week High 0.02
52 Week Low 0.01
ACL Important Levels
Resistance 2 0.01
Resistance 1 0.01
Pivot 0.01
Support 1 0.01
Support 2 0.01
ASX Australia Most Active Stocks
COE 0.30 3.45%
COE 0.30 3.45%
GPP 0.02 0.00%
DUE 3.02 1.00%
DUE 3.02 1.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
AGO 0.02 0.00%
AGO 0.02 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
XST 0.02 100.00%
XST 0.02 100.00%
ATP 0.03 50.00%
ATP 0.03 50.00%
PMQ 0.03 50.00%
RMI 0.03 50.00%
RMI 0.03 50.00%
BNV 0.03 50.00%
IRM 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
EMG 0.01 -50.00%
GDY 0.01 -50.00%
More..

Alchemia Ltd (ASX: ACL)

ACL Technical Analysis 5
As on 31st Oct 2017 ACL Share Price closed @ 0.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.01 & Strong Sell for SHORT-TERM with Stoploss of 0.01 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACL Target for December
1st Target up-side 0.01
2nd Target up-side 0.01
3rd Target up-side 0.01
1st Target down-side 0.01
2nd Target down-side 0.01
3rd Target down-side 0.01
ACL Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.alchemia.com.au
ACL Address
ACL
3 Hi
Eight Mile Plains
Brisbane, QLD 4113
Australia
Phone: 61 7 3340 0200
Fax: 61 7 3340 0222
ACL Latest News
Interactive Technical Analysis Chart Alchemia Ltd ( ACL ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alchemia Ltd
ACL Business Profile
Alchemia Limited, a biotechnology company, is engaged in the discovery and development of human therapeutic products based on its proprietary drug discovery, drug targeting, and synthesis technologies primarily in Australia. The company’s technologies include HyACT drug delivery technology that enhances the delivery of chemotherapeutic agents to cancer cells; and Versatile Assembly on Stable Templates technology, a small molecule drug discovery technology. It also provides generic fondaparinux, an injectable anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. In addition, the company develops HA-Irinotecan that is in Phase III clinical trials for the treatment of metastatic colorectal cancer. It has collaboration with Monash Institute of Pharmaceutical Science to discover drug candidates for G-Protein coupled receptors; and University of Queensland to discover novel opioid analgesics with reduced side effects. The company was founded in 1995 and is headquartered in Brisbane, Australia.